At the time of writing, Amylyx Pharmaceuticals Inc [AMLX] stock is trading at $8.5, down -8.60%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AMLX shares have gain 6.38% over the last week, with a monthly amount glided 4.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on June 24, 2025, and set its price target to $17. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $12 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Mizuho upgraded its rating to a Outperform but $7 remained the price target by the analyst firm on April 07, 2025. Robert W. Baird upgraded its rating to Outperform for this stock on November 18, 2024, and upped its price target to $11. In a note dated October 23, 2024, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $4.20 to $10.
For the past year, the stock price of Amylyx Pharmaceuticals Inc fluctuated between $2.05 and $9.38. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $8.5 at the most recent close of the market. An investor can expect a potential return of 58.82% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
According to Amylyx Pharmaceuticals Inc [NASDAQ:AMLX], the company’s sales were -0.25M for trailing twelve months, which represents an 100.00% jump. Gross Profit Margin for this corporation currently stands at 5.46% with Operating Profit Margin at 791.06%, Pretax Profit Margin comes in at 755.96%, and Net Profit Margin reading is 753.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.96, Equity is -1.03 and Total Capital is -1.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.20 points at the first support level, and at 7.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.08, and for the 2nd resistance point, it is at 9.65.
Ratios To Look Out For
It is important to note that Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] has a current ratio of 8.72. As well, the Quick Ratio is 8.72, while the Cash Ratio is 2.71.
Transactions by insiders
Recent insider trading involved Mazzariello Gina, Chief Legal Officer, that happened on Aug 13 ’25 when 15000.0 shares were sold. Chief Legal Officer, Mazzariello Gina completed a deal on Aug 12 ’25 to sell 15000.0 shares. Meanwhile, Officer GINA MAZZARIELLO bought 30000.0 shares on Aug 12 ’25.
